Bleeding risk evaluation in cerebral cavernous malformation, the role of medications, and hemorrhagic factors: a case-control study
Neurosurgical Focus · 2023
DOI: 10.3171/2023.7.focus23355 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Neurosurgical Focus, 2023. Verfasst von Alba Scerrati und 12 weiteren Autor:innen. Beteiligte Einrichtung: Departments of1Translational Medicine and. Hauptthemen laut MEDLINE: Hemangioma, Cavernous, Central Nervous System, Hypertension. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 66 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE Cerebral cavernous malformations (CCMs) are vascular lesions with an overall risk of rupture from 2% to 6% per year, which is associated with significant morbidity and mortality. The diagnostic incidence is increasing, so it is of paramount importance to stratify patients based on their risk of rupture. Data in the literature seem to suggest that specific medications, particularly antithrombotic and cardiovascular agents, are associated with a reduced risk of bleeding. However, the effect of the patient coagulative status on the cumulative bleeding risk remains unclear. The aim of this study was to assess the impact of different radiological, clinical, and pharmacological factors on the bleeding risk of CCMs and to assess the predictive power of an already validated scale for general bleeding risk, the HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol concomitantly). METHOD This was a multicenter retrospective observational study. The authors collected imaging, clinical status, and therapy data on patients with bleeding and nonbleeding CCMs. Univariate analysis and subsequent multivariate logistic regression were performed between the considered variables and bleeding or nonbleeding status to identify potential independent predictors of bleeding. RESULTS The authors collected data on 257 patients (46.7% male, 25.3% with bleeding CCMs). Compared with patients with nonbleeding lesions, those with bleeding CCMs were younger, less frequently had hypertension, and less frequently required antiplatelet drugs and beta-blockers (all p < 0.05). Bleeding lesions, however, had significantly higher median volumes (1050 mm 3 vs 523 mm 3 , p < 0.001). On multivariate analyses, after adjusting for age, history of hypertension and diabetes, and use of antiplatelet drugs or beta-blockers, lesion volume ≥ 300 mm 3 was the only significant predictor of bleeding (adjusted OR 3.11, 95% CI 1.09–8.86). When the diagnostic accuracy of different volume thresholds was explored, volume ≥ 300 mm 3 showed a limited sensitivity (36.7%, 95% CI 24.6%–50.0%), but a high specificity 78.2% (95% CI 71.3%–84.2%), with an area under the curve of 0.57 (95% CI 0.51–0.64). CONCLUSIONS This study supports previous findings that the CCM volume is the only factor influencing the bleeding risk. Antithrombotic agents and propranolol seem to have a protective role against the bleeding events. A high HAS-BLED score was not associated with an increased bleeding risk. Further studies are needed to confirm these results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of1Translational Medicine and.
- 2Department of Neurosurgery, University Hospital S. Anna of Ferrara.
- 3Department of Neuroscience "Rita Levi Montalcini," Neurosurgery Unit, University of Turin; and.
- 4Environmental and Preventive Sciences, University of Ferrara.
- 5Department of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of Sacred Heart, Rome, Italy.
Zitieren
APA
Scerrati, A., Mantovani, G., Travaglini, F., Bradaschia, L., De Bonis, P., Farneti, M., Cavallo, M. A., Dones, F., Flacco, M. E., Auricchio, A. M., Benato, A., Albanese, A., & Sturiale, C. L. (2023). Bleeding risk evaluation in cerebral cavernous malformation, the role of medications, and hemorrhagic factors: a case-control study. Neurosurgical Focus. https://doi.org/10.3171/2023.7.focus23355
Vancouver
Scerrati A, Mantovani G, Travaglini F, Bradaschia L, De Bonis P, Farneti M, et al. Bleeding risk evaluation in cerebral cavernous malformation, the role of medications, and hemorrhagic factors: a case-control study. Neurosurgical Focus. 2023. doi:10.3171/2023.7.focus23355
BibTeX
@article{Scerrati2023,
author = {Scerrati, Alba and Mantovani, Giorgio and Travaglini, Francesco and Bradaschia, Leonardo and De Bonis, Pasquale and Farneti, Marco and Cavallo, Michele Alessandro and Dones, Flavia and Flacco, Maria Elena and Auricchio, Anna Maria and Benato, Alberto and Albanese, Alessio and Sturiale, Carmelo Lucio},
title = {Bleeding risk evaluation in cerebral cavernous malformation, the role of medications, and hemorrhagic factors: a case-control study},
journal = {Neurosurgical Focus},
year = {2023},
doi = {10.3171/2023.7.focus23355}
}
EUVIMED